Current Cardiology Reports

, Volume 9, Issue 2, pp 150–158

The role and regulation of cardiac angiotensin-converting enzyme for noninvasive molecular imaging in heart failure

  • Omer Aras
  • Steven A. Messina
  • Jamshid Shirani
  • William C. Eckelman
  • Vasken Dilsizian
Nuclear Cardiology

Abstract

Congestive heart failure is a pathologic condition characterized by progressive decrease in left ventricular contractility and consequent decline of cardiac output. There is convincing clinical and experimental evidence that the renin-angiotensin system (RAS) and its primary effector peptide, angiotensin II, are linked to the pathophysiology of interstitial fibrosis, cardiac remodeling, and heart failure. In addition to the traditional endocrine or circulating RAS, an active tissue RAS has been characterized. Tissue angiotensin-converting enzyme and locally synthesized angiotensin II, for example, by chymase, exert local trophic effects that modulate gene expression, which regulates growth and proliferation in both myocytes and nonmyocytes. The existence of the tissue RAS offers an opportunity for targeted imaging, which may be of considerable value for guiding medical therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Levy D, Kenchaiah S, Larson MG, et al.:Long-term trends in the incidence of and survival with heart failure.N Engl J Med 2002,347:1397–1402.PubMedCrossRefGoogle Scholar
  2. 2.
    Hunt SA, Baker DW, Chin MH, et al.:ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America.Circulation 2001,104:2996–3007.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohn JN, Ferrari R, Sharpe N:Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.J Am Coll Cardiol 2000,35:569–582.PubMedCrossRefGoogle Scholar
  4. 4.
    Harada K, Sugaya T, Murakami K, et al.:Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction.Circulation 1999,100:2093–2099.PubMedGoogle Scholar
  5. 5.
    Of major importance Dilsizian V, Eckelman WC, Loredo ML, et al.:Evidence for tissue angiotensin-converting-enzyme in explanted hearts of ischemic cardiomyopathy using targeted radiotracer technique.J Nucl Med 2007,48:182–187.18F-fluorobenzoyl-lisinopril was shown to bind specifically to local tissue ACE in explanted human hearts with the highest activity in regions adjacent to infarcted myocardium.PubMedGoogle Scholar
  6. 6.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.N Engl J Med 1991,325:293–302.Google Scholar
  7. 7.
    Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors.N Engl J Med 1992,327:685–691.Google Scholar
  8. 8.
    Riordan JF:Angiotensin-I-converting enzyme and its relatives.Genome Biol 2003,4:225.PubMedCrossRefGoogle Scholar
  9. 9.
    Hooper NM, Keen J, Pappin DJ, et al.:Pig kidney angiotensin converting enzyme. Purification and characterization of amphipathic and hydrophilic forms of the enzyme establishes C-terminal anchorage to the plasma membrane.Biochem J 1987,247:85–93.PubMedGoogle Scholar
  10. 10.
    Of importance Paul M, Poyan MA, Kreutz R:Physiology of local reninangiotensin systems.Physiol Rev 2006,86:747–803. This is comprehensive and authoritative review of local RAS and its various components, including cardiac RAS.PubMedCrossRefGoogle Scholar
  11. 11.
    Dzau VJ, Bernstein K, Celermajer D, et al.:The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data.Am J Cardiol 2001,88:1L-20L.PubMedCrossRefGoogle Scholar
  12. 12.
    Dzau VJ:Implications of local angiotensin production in cardiovascular physiology and pharmacology.Am J Cardiol 1987,59:59A-65A.PubMedCrossRefGoogle Scholar
  13. 13.
    Bader M:Role of the local renin-angiotensin system in cardiac damage: a minireview focusing on transgenic animal models.J Mol Cell Cardiol 2002,34:1455–1462.PubMedCrossRefGoogle Scholar
  14. 14.
    Schunkert H, Dzau VJ, Tang SS, et al.:Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation.J Clin Invest 1990,86:1913–1920.PubMedCrossRefGoogle Scholar
  15. 15.
    Passier RC, Smits JF, Verluyten MJ, et al.:Activation of angiotensin-converting enzyme expression in infarct zone following myocardial infarction.Am J Physiol 1995,269: H1268-H1276.PubMedGoogle Scholar
  16. 16.
    Yamada H, Fabris B, Allen AM, et al.:Localization of angiotensin converting enzyme in rat heart.Circ Res 1991,68:141–149.PubMedGoogle Scholar
  17. 17.
    Fleming I, Kohlstedt K, Busse R:The tissue renin-angiotensin system and intracellular signalling.Curr Opin Nephrol Hypertens 2006,15:8–13.PubMedCrossRefGoogle Scholar
  18. 18.
    Dostal DE, Baker KM:The cardiac renin-angiotensin system: conceptual, or a regulator of cardiac function? Circ Res 1999,85:643–650.PubMedGoogle Scholar
  19. 19.
    Baker KM, Aceto JF:Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells.Am J Physiol. 1990,259:H610-H618.PubMedGoogle Scholar
  20. 20.
    Baker KM, Chernin MI, Wixson SK, et al.:Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats.Am J Physiol 1990,259:H324-H332.PubMedGoogle Scholar
  21. 21.
    Sadoshima J, Xu Y, Slayter HS, et al.:Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro.Cell 1993,75:977–984.PubMedCrossRefGoogle Scholar
  22. 22.
    Sun Y, Zhang J, Lu L, et al.:Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.J Lab Clin Med 2004,143:41–51.PubMedCrossRefGoogle Scholar
  23. 23.
    Weber KT, Sun Y:Recruitable ACE and tissue repair in the infarcted heart.J Renin Angiotensin Aldosterone Syst 2000,1:295–303.PubMedCrossRefGoogle Scholar
  24. 24.
    Zisman LS, Asano K, Dutcher DL: et al.:Differential regulation of cardiac angiotensin converting enzyme binding sites and AT1 receptor density in the failing human heart.Circulation 1998,98:1735–1741.PubMedGoogle Scholar
  25. 25.
    Zisman LS, Abraham WT, Meixell GE, et al.:Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway.J Clin Invest 1995,96:1490–1498.PubMedCrossRefGoogle Scholar
  26. 26.
    Urata H, Hoffmann S, Ganten D.Tissue angiotensin II system in the human heart.Eur Heart J 1994,15(Suppl D): 68–78.PubMedGoogle Scholar
  27. 27.
    Miyazaki M, Takai S:Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase.J Pharmacol Sci 2006,100:391–397.PubMedCrossRefGoogle Scholar
  28. 28.
    Unger T, Li J:The role of the renin-angiotensin-aldosterone system in heart failure.J Renin Angiotensin Aldosterone Syst 2004,5(Suppl 1):S7–10.CrossRefGoogle Scholar
  29. 29.
    Patella V, Marino I, Arbustini E, et al.:Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy.Circulation 1998,97:971–978.PubMedGoogle Scholar
  30. 30.
    Sukenaga Y, Kamoshita K, Takai S, et al.:Development of the chymase inhibitor as an anti-tissue-remodeling drug: myocardial infarction and some other possibilities Jpn J Pharmacol 2002,90:218–222.PubMedCrossRefGoogle Scholar
  31. 31.
    Matsumoto T, Wada A, Tsutamoto T, et al.:Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.Circulation 2003,107:2555–2558.PubMedCrossRefGoogle Scholar
  32. 32.
    Kokkonen JO, Lindstedt KA, Kovanen PT:Role for chymase in heart failure: angiotensin II-dependent or-independent mechanisms? Circulation 2003,107:2522–2524.PubMedCrossRefGoogle Scholar
  33. 33.
    Mackins CJ, Kano S, Seyedi N, et al.:Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion.J Clin Invest 2006,116:1063–1070.PubMedCrossRefGoogle Scholar
  34. 34.
    Of major importance Batlle M, Roig E, Perez-Villa F, et al.:Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure.J Heart Lung Transplant 2006,25:1117–1125. Chymase, ACE, and ACE2 expression and mast cell density were analyzed simultaneously in left ventricular samples obtained from patients with heart failure undergoing heart transplantation.PubMedCrossRefGoogle Scholar
  35. 35.
    Serneri GG, Boddi M, Cecioni I, et al.:Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function.Circ Res 2001,88:961–968.PubMedCrossRefGoogle Scholar
  36. 36.
    Zisman LS, Keller RS, Weaver B, et al.:Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2.Circulation 2003,108:1707–1712.PubMedCrossRefGoogle Scholar
  37. 37.
    Der SS, Huentelman MJ, Stewart J, et al.:ACE2: A novel therapeutic target for cardiovascular diseases.Prog Biophys Mol Biol 2006,91:163–198.CrossRefGoogle Scholar
  38. 38.
    Danilczyk U, Eriksson U, Oudit, GY, et al.:Physiological roles of angiotensin-converting enzyme 2.Cell Mol Life Sci 2004,61:2714–2719.PubMedCrossRefGoogle Scholar
  39. 39.
    Of importance Ferrario CM, Trask AJ, Jessup JA:Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular function.Am J Physiol Heart Circ Physiol 2005,289: H2281-H2290. This review summarizes the current understanding of the ACE2 and Ang-(1–7) in regulation of cardiovascular function.PubMedCrossRefGoogle Scholar
  40. 40.
    Donoghue M, Hsieh F, Baronas E, et al.:A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9.Circ Res 2000,87:E1-E9.PubMedGoogle Scholar
  41. 41.
    Crackower MA, Sarao R, Oudit GY, et al.:Angiotensin-converting enzyme 2 is an essential regulator of heart function.Nature 2002,417:822–828.PubMedCrossRefGoogle Scholar
  42. 42.
    Yamamoto K, Ohishi M, Katsuya T, et al.:Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.Hypertension 2006,47:718–726.PubMedCrossRefGoogle Scholar
  43. 43.
    Of major importance Tian XL, Pinto YM, Costerousse O, et al.:Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats.Hum Mol Genet 2004,13:1441–1450. A transgenic rat model with selective overexpression of human ACE1 in the cardiac ventricles was first described.PubMedCrossRefGoogle Scholar
  44. 44.
    Sun Y, Cleutjens JP, Diaz-Arias AA, et al.:Cardiac angiotensin converting enzyme and myocardial fibrosis in the rat.Cardiovasc Res 1994,28:1423–1432.PubMedCrossRefGoogle Scholar
  45. 45.
    Of major importance Pokharel S, van Geel PP, Sharma UC, et al.:Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3.Circulation 2004,110:3129–3135. In transgenic rats overexpressing cardiac ACE, primary and selective increase of cardiac ACE activity was associated with increased cardiac collagen deposition caused by excessive breakdown of cardiac AcSDKP.PubMedCrossRefGoogle Scholar
  46. 46.
    Rousseau A, Michaud A, Chauvet MT, et al.:The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.J Biol Chem 1995,270:3656–3661.PubMedCrossRefGoogle Scholar
  47. 47.
    Of major importance Peng H, Carretero OA, Vuljaj N, et al.:Angiotensin-converting enzyme inhibitors: a new mechanism of action.Circulation 2005,112:2436–2445. A novel mechanism of the cardiac antifibrotic effect of ACE inhibition was reported involving blockade of the hydrolysis of AcSDKP in an animal model.PubMedCrossRefGoogle Scholar
  48. 48.
    Pradelles P, Frobert Y, Creminon C, et al.:Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay.Biochem Biophys Res Commun 1990,170:986–993.PubMedCrossRefGoogle Scholar
  49. 49.
    Zhuo JL, Carretero OA, Peng H, et al.:Characterization of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) receptor binding sites using [125I]-Hpp-Aca-SDKP in rat cardiac fibroblasts.Am J Physiol Heart Circ Physiol 2006, in press.Google Scholar
  50. 50.
    Ikeuchi M, Tsutsui H, Shiomi T, et al.:Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction.Cardiovasc Res 2004,64:526–535.PubMedCrossRefGoogle Scholar
  51. 51.
    Tiret L, Rigat B, Visvikis S, et al.:Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels.Am J Hum Genet 1992,51:197–205.PubMedGoogle Scholar
  52. 52.
    Danser AH, Derkx FH, Hense HW, et al.:Angiotensinogen (M235T) and angiotensin-converting enzyme (I/D) polymorphisms in association with plasma renin and prorenin levels.J Hypertens 1998,16:1879–1883.PubMedCrossRefGoogle Scholar
  53. 53.
    Andersson B, Blange I, Sylven C:Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure.Eur J Heart Fail 1999,1:363–369.PubMedCrossRefGoogle Scholar
  54. 54.
    Andersson B, Sylven C:The DD genotype of the angiotensin-converting enzyme gene is associated with increased mortality in idiopathic heart failure.J Am Coll Cardiol 1996,28:162–167.PubMedCrossRefGoogle Scholar
  55. 55.
    Danser AH, Schalekamp MA, Bax WA, et al.:Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.Circulation 1995,92:1387–1388.PubMedGoogle Scholar
  56. 56.
    Davis GK, Millner RW, Roberts DH:Angiotensin converting enzyme (ACE) gene expression in the human left ventricle: effect of ACE gene insertion/deletion polymorphism and left ventricular function.Eur J Heart Fail 2000,2:253–256.PubMedCrossRefGoogle Scholar
  57. 57.
    Cicoira M, Zanolla L, Rossi A, et al.:Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype.J Am Coll Cardiol 2001,37:1808–1812.PubMedCrossRefGoogle Scholar
  58. 58.
    Of importance McNamara DM, Holubkov R, Postava L, et al.:Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure.J Am Coll Cardiol 2004,44:2019–2026. Pharmacogenetic interaction between the ACE D/I polymorphism and the impact of ACE inhibitor dose on heart failure survival was shown.PubMedCrossRefGoogle Scholar
  59. 59.
    Candy GP, Skudicky D, Mueller UK, et al.:Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy.Am J Cardiol 1999,83:740–744.PubMedCrossRefGoogle Scholar
  60. 60.
    Dellgren G, Eriksson MJ, Blange I, et al.:Angiotensin-converting enzyme gene polymorphism influences degree of left ventricular hypertrophy and its regression in patients undergoing operation for aortic stenosis.Am J Cardiol 1999,84:909–913.PubMedCrossRefGoogle Scholar
  61. 61.
    Schunkert H, Hense HW, Holmer SIR, et al.:Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.N Engl J Med 1994,330:1634–1638.PubMedCrossRefGoogle Scholar
  62. 62.
    Lindpaintner K, Lee M, Larson MG, et al.:Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass.N Engl J Med 1996,334:1023–1028.PubMedCrossRefGoogle Scholar
  63. 63.
    Fyhrquist F, Tikkanen I, Gronhagen-Riska C, et al.:Inhibitor binding assay for angiotensin-converting enzyme.Clin Chem 1984,30:696–700.PubMedGoogle Scholar
  64. 64.
    Shirani J, Loredo ML, Eckelman WC, et al.:Imaging the renin-angiotensin-aldosterone system in the heart.Curr Heart Fail Rep 2005,2:78–86.PubMedCrossRefGoogle Scholar
  65. 65.
    Matarrese M, Salimbeni A, Turolla EA, et al.:11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat.Bioorg Med Chem 2004,12:603–611.PubMedCrossRefGoogle Scholar
  66. 66.
    Lee YHC, Kiesewetter DO, Lang L, et al.:Symthesis of 4-[18F] fluorobenzoyllisinopril: a radioligand for angiotensin converting enzyme (ACE) imaging with positron emission tomography.J Labelled Comp Radiopharm 2001,44: S268-S270.Google Scholar
  67. 67.
    Fernia FJ, Maresca KP, Joyal JL, et al.:Synthesis and evaluation of radioligands for angiotensin-converting enzyme (ACE) imaging.J Nucl Med 2006,5:260P.Google Scholar
  68. 68.
    Johnston CI, Fabris B, Yamada H, et al.:Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.J Hypertens Suppl 1989,7:S11-S16.PubMedGoogle Scholar
  69. 69.
    Schunkert H, Jackson B, Tang SS, et al.:Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts.Circulation 1993,87:1328–1339.PubMedGoogle Scholar
  70. 70.
    Kohzuki M, Kanazawa M, Yoshida K, et al.:Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.Jpn Circ J 1996,60:972–980.PubMedCrossRefGoogle Scholar
  71. 71.
    Schuster DP, McCarthy TJ, Welch MJ, et al.:In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II. Implementation and application.J Appl Physiol 1995,78:1169–1178.PubMedGoogle Scholar
  72. 72.
    Moskowitz DW:From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.Diabetes Technol Ther 2002,4:519–532.PubMedCrossRefGoogle Scholar
  73. 73.
    Mathews WB, Burns HD, Dannals RF:Carbon-11 labeling of the potent nonpeptide angiotensin-II antagonist MK-996.J Labelled Comp Radiopharm 1995,36:729–737.CrossRefGoogle Scholar
  74. 74.
    Hamill TG, Burns HD, Dannals RF, et al.:Development of [11C]L-159,884: a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging.Appl Radiat Isot 1996,47:211–218.PubMedCrossRefGoogle Scholar
  75. 75.
    Szabo Z, Speth RC, Brown PR, et al.:Use of positron emission tomography to study AT1 receptor regulation in vivo.J Am Soc Nephrol 2001,12:1350–1358.PubMedGoogle Scholar
  76. 76.
    Lee SH, Jung YS, Lee BH, et al.:Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.J Cardiovasc Pharmacol 1999,33:367–374.PubMedCrossRefGoogle Scholar
  77. 77.
    Verjans J, Lovhaug D, Narula N:Noninvasive imaging of myocardial angiotensin receptors in heart failure. 25th Annual Scientific Sessions of Western States Affiliates of American Heart Association. Irvine, CA: September 30, 2005.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Omer Aras
  • Steven A. Messina
  • Jamshid Shirani
  • William C. Eckelman
  • Vasken Dilsizian
    • 1
  1. 1.Division of Nuclear Medicine, Department of Diagnostic RadiologyUniversity of Maryland Hospital and School of MedicineBaltimoreUSA

Personalised recommendations